Lataz-Co (Timolol Maleate, Latanoprost)

• Lataz-Co is used in ophthalmology to manage conditions characterized by elevated intra‑ocular pressure.
• Open‑angle glaucoma: reduces pressure to prevent progressive optic nerve damage.
• Ocular hypertension: lowers eye pressure to reduce risk of developing glaucoma.
• Pseudoexfoliative glaucoma: provides pressure reduction in this secondary form of open‑angle glaucoma.

• Timolol maleate blocks beta‑adrenergic receptors in the ciliary body, decreasing aqueous humor production, while Latanoprost activates prostaglandin F receptors, enhancing uveoscleral outflow of aqueous humor. The combined actions result in a synergistic reduction of intra‑ocular pressure, addressing both production and drainage pathways.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision shortly after instillation
• Redness of the conjunctiva
• Itching or mild allergic reaction on the eyelid
• Dry eye sensation
• Foreign body feeling in the eye

Serious or Rare Side Effects

• Severe allergic reaction with swelling of the eyelid or face
• Persistent eye pain or worsening vision loss
• Corneal ulcer or keratitis
• Systemic bradycardia or hypotension due to beta‑blocker absorption
• Acute angle‑closure glaucoma precipitated by prostaglandin effect
• Respiratory distress in patients with asthma

• Before initiating therapy, evaluate patient medical history and concomitant medications.
• Cardiovascular assessment: monitor heart rate and blood pressure in patients with cardiac disease.
• Respiratory caution: avoid use in patients with severe asthma or chronic obstructive pulmonary disease.
• Concurrent beta‑blockers: use with caution when systemic beta‑blockers are prescribed.
• Contact lens wear: advise removal of soft lenses before instillation and for at least 15 minutes after.
• Allergy screening: check for hypersensitivity to any component of the formulation.
• Store at room temperature: keep in the original container, protect from light and moisture.

Lataz-Co may interact with other medications affecting intra‑ocular pressure or systemic beta‑adrenergic activity.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): risk of additive bradycardia and hypotension.
• Inhaled beta‑agonists (e.g., albuterol): may reduce ocular efficacy of timolol.
• Monoamine oxidase inhibitors: potential for enhanced ocular hypotensive effect.

Moderate Interactions (Monitor Closely):\n- Other intra‑ocular pressure‑lowering agents (e.g., carbonic anhydrase inhibitors, other prostaglandin analogs): may increase pressure‑lowering effect.

• Anticholinergic eye drops: could diminish timolol absorption.
• NSAID eye preparations: monitor for additive ocular irritation.